Cogent Biosciences, Inc.

This program provides early access to an investigational drug, bezuclastinib, to be given alongside the existing drug sunitinib for adults with advanced gastrointestinal stromal tumors (GIST). It is for patients whose cancer has progressed after standard treatment and who have no…

This program provides access to the investigational drug bezuclastinib for adults with systemic mastocytosis, a rare disorder where too many mast cells build up in the body. It is for patients whose current treatments are not working well or who have no other good treatment optio…

This early-stage study is testing a new oral drug called CGT4255 in adults with advanced solid tumors that have specific genetic changes (ERBB2 alterations or HER2 overexpression). The main goals are to find a safe dose and see if the drug can shrink tumors, including those that …